Claims for Patent: 8,088,789

Summary for Patent: 8,088,789

Title:	Macrocyclic lactone compounds and methods for their use
Abstract:	A method of treating an ophthalmic condition or disease by administering a compound disclosed herein is provided. The compound can be administered systemically or locally and in a variety of ways, such as via a temporary device, an implant, an injection or an eye drop. The compound can also be administered with an additional therapeutic agent.
Inventor(s):	Yan; John (Los Gatos, CA), Zheng; Xiaoxia (Mountain View, CA), Bhat; Vinayak D. (Cupertino, CA)
Assignee:	Elixir Medical Corporation (Sunnyvale, CA)
Application Number:	12/046,024
Patent Claims:	1. A method of treating an ophthalmic condition or disease, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the formula: ##STR00279## wherein R.sup.4, R.sup.7 and R.sup.9 are each independently selected from the group consisting of --OCH.sub.3 and OH; R.sup.10 is a member selected from the group consisting of H, --OH, --OP(O)Me.sub.2, ##STR00280## --O--(CH.sub.2).sub.n--OH and --O--(CH.sub.2).sub.m--O--(CH.sub.2).sub.o--CH.sub.3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; with the proviso that when R.sup.4, R.sup.7 and R.sup.9 are each --OCH.sub.3, R.sup.10 is other than --OH, --OP(O)Me.sub.2, ##STR00281## --O--(CH.sub.2).sub.n--OH and --O--(CH.sub.2).sub.m--O--(CH.sub.2).sub.o--CH.sub.3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; or a salt, isomer, or N-oxide thereof, thereby treating the ophthalmic condition or disease. 2. The method of claim 1, wherein the ophthalmic condition or disease is a member selected from the group consisting of disorders of the eyelid, disorders of the lacrimal system and orbit, tear duct blockage, disorders of conjunctiva, disorders of the sclera, cornea, iris and ciliary body, disorders of the lens, disorders of the choroid and retina, Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), glaucoma, disorders of the vitreous body and globe, disorders of the optic nerve and visual pathways, disorders of the ocular muscles, binocular movement, accommodation and refraction, visual disturbances and disorders leading to blindness. 3. The method of claim 1, wherein the method of treating is selected from the group consisting of reducing cell proliferation, reducing inflammation, reducing cytokine production, reducing neovascularization, treating neurovascular system, and reducing immune response after transplantation. 4. The method of claim 1, wherein the compound is administered via an implant, an injection or an eye drop. 5. The method of claim 4, wherein administration is to the ocular body of the eye, the intraocular body of the eye, the vitreal body of the eye, or the intravitreal body of the eye. 6. The method of claim 4, wherein administration is via the implant. 7. The method of claim 6, wherein the compound is released from the implant via osmotic pressure or diffusion. 8. The method of claim 1, wherein at least one of R.sup.4, R.sup.7, and R.sup.9 is OH. 9. The method of claim 8, wherein R.sup.4 is OH. 10. The method of claim 9, wherein R.sup.4 and R.sup.10 are each OH; and R.sup.7 and R.sup.9 are each OMe. 11. The method of claim 1, wherein the compound is administered in combination with at least one additional therapeutic agent. 12. The method of claim 11, wherein the additional therapeutic agent is a member selected from the group consisting of heparin, clopidogrel, coumadin, aspirin, ticlid, diclofenac, indomethacin, sulindac, ketoprofen, flurbiprofen, ibuprofen, naproxen, piroxicam, tenoxicam, tolmetin, ketorolac, oxaprosin, mefenamic acid, fenoprofen, nabumetone, acetaminophen, nimesulide, NS-398, flosulid, L-745337, celecoxib, rofecoxib, SC-57666, DuP-697, parecoxib sodium, JTE-522, valdecoxib, SC-58125, etoricoxib, RS-57067, L-748780, L-761066, o-(acetoxyphenyl)hept-2-ynyl sulfide (APHS), etodolac, meloxicam, S-2474, tacrolimus, hydrocortisone, cortisone, prednisone, prednisolone, methylprednisolone, meprednisone, triamcinolone, paramethasone, fluprednisolone, betamethasone, dexamethasone, fludrocortisone, desoxycorticosterone, rapamycin, and cyclosporine. 13. The method of claim 11, wherein the additional therapeutic agent is a member selected from the group consisting of ranibizumab, bevacizumab, pegaptanib, volociximab, olopatadine, mydriatcs, dexamethasone, pilocarpine, tropicamide, quinolone, galentamine, fluocinolone acetonide, triamcinolone acetonide, atropine, atropine sulfate, atropine hydrochloride, atropine methylbromide, atropine methyl nitrate, atropine hyperduric, atropine N-oxide, phenylephrine, phenylephrine hydrochloride, hydroxyamphetamine, hydroxyamphetamine hydrobromide, hydroxyamphetamine hydrochloride, hydroxyamphetamine iodide, cyclopentolate, cyclopentolate hydrochloride, homatropine, homatropine hydrobromide, homatropine hydrochloride, homatropine methylbromide, scopolamine, scopolamine hydrobromide, scopolamine hydrochloride, scopolamine methylbromide, scopolamine methylnitrate, scopolamine N-oxide, tropicamide, tropicamide hydrobromide, tropicamide hydrochloride, pilocarpine, isopilocarpine, physostigmine, stearyl ammonium chloride and benzyl ammonium chloride. 14. The method of claim 1, wherein the compound is administered with a pharmaceutically acceptable excipient. 15. The method of claim 14, wherein the pharmaceutically acceptable excipient is selected from the group consisting of polymers, solvents, antioxidants, binders, fillers, disintegrants, lubricants, coatings, sweetening agents, flavoring agents, perfuming agents, stabilizers, colorants, metals, ceramics, semi-metals, preserving agents, glidants, wetting agents, emulsifying agents, suspending agents, dispensing agents, and acidifying agents. 16. The method of claim 1, wherein the compound is administered systemically or locally, or a combination thereof. 17. The method of claim 1, wherein administration of the compound is via delivery from a temporary device or an implant. 18. The method of claim 17, wherein the temporary device or implant is configured to release the compound to a body lumen or organ within an intracorporeal body. 19. The method of claim 1, wherein the effective dose of the compound is from about 0.1 mg to about 20 mg. 20. The method of claim 1, wherein the effective dose of the compound is from about 0.5 mg to about 10 mg. 21. The method of claim 1, wherein the effective dose of the compound is from about 1 mg to about 5 mg. 22. The method of claim 1, wherein the compound is racemic at the C-16 position. 23. The method of claim 1, wherein the compound has an (R)-stereochemistry at the C-16 position. 24. The method of claim 1, wherein the compound has an (S)-stereochemistry at the C-16 position. 25. A method of treating an ophthalmic condition or disease, comprising administering a composition to a subject in need thereof, wherein a tissue in the subject is exposed to an effective concentration of a compound of formula: ##STR00282## or a salt, isomer, or N-oxide thereof, thereby treating the ophthalmic condition or disease. 26. The method of treating an ophthalmic condition or disease as in claim 25, wherein the tissue in the subject is exposed to at least about 100 ng/gm tissue of the compound. 27. A method comprising ophthalmic administration to a subject of a macrocyclic lactone of a compound of formula: ##STR00283## wherein an ocular tissue in the subject is exposed to a concentration of the compound. 28. The method of claim 27 wherein the ocular tissue in the subject is exposed to at least about 100 ng/gm tissue of the compound.

Details for Patent 8,088,789

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2026-09-13
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006		2026-09-13
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012		2026-09-13
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016		2026-09-13